AU2020337883B2 - Heterocyclic pyrazole derivatives as type III receptor tyrosine kinase inhibitors - Google Patents

Heterocyclic pyrazole derivatives as type III receptor tyrosine kinase inhibitors

Info

Publication number
AU2020337883B2
AU2020337883B2 AU2020337883A AU2020337883A AU2020337883B2 AU 2020337883 B2 AU2020337883 B2 AU 2020337883B2 AU 2020337883 A AU2020337883 A AU 2020337883A AU 2020337883 A AU2020337883 A AU 2020337883A AU 2020337883 B2 AU2020337883 B2 AU 2020337883B2
Authority
AU
Australia
Prior art keywords
indazol
dihydrothieno
cyclopenta
methyl
methy1
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
AU2020337883A
Other languages
English (en)
Other versions
AU2020337883A1 (en
Inventor
Yi-Mei CHANG
Yuan-Ting Cho
Hung-Jyun HUANG
Chu-Bin Liao
Yu-Chih PAN
Shao-Zheng Peng
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Development Center for Biotechnology
Original Assignee
Development Center for Biotechnology
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Development Center for Biotechnology filed Critical Development Center for Biotechnology
Publication of AU2020337883A1 publication Critical patent/AU2020337883A1/en
Application granted granted Critical
Publication of AU2020337883B2 publication Critical patent/AU2020337883B2/en
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D495/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
    • C07D495/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D495/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/415—1,2-Diazoles
    • A61K31/4162—1,2-Diazoles condensed with heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/54—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame
    • A61K31/541—Non-condensed thiazines containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
AU2020337883A 2019-08-23 2020-08-22 Heterocyclic pyrazole derivatives as type III receptor tyrosine kinase inhibitors Active AU2020337883B2 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201962891097P 2019-08-23 2019-08-23
US62/891,097 2019-08-23
PCT/US2020/047552 WO2021041276A1 (en) 2019-08-23 2020-08-22 Heterocyclic pyrazole derivatives as type iii receptor tyrosine kinase inhibitors

Publications (2)

Publication Number Publication Date
AU2020337883A1 AU2020337883A1 (en) 2022-03-24
AU2020337883B2 true AU2020337883B2 (en) 2025-08-28

Family

ID=74685735

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2020337883A Active AU2020337883B2 (en) 2019-08-23 2020-08-22 Heterocyclic pyrazole derivatives as type III receptor tyrosine kinase inhibitors

Country Status (11)

Country Link
US (1) US12448394B2 (https=)
EP (1) EP4017853A4 (https=)
JP (1) JP7651557B2 (https=)
KR (1) KR20220051365A (https=)
CN (1) CN114502553B (https=)
AU (1) AU2020337883B2 (https=)
BR (1) BR112022003383A2 (https=)
CA (1) CA3151821A1 (https=)
MX (1) MX2022002062A (https=)
TW (1) TWI759829B (https=)
WO (1) WO2021041276A1 (https=)

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20130274255A1 (en) * 2012-04-12 2013-10-17 Development Center For Biotechnology Heterocyclic pyrazole compounds, method for preparing the same and use thereof

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2323952T3 (es) 2002-05-15 2009-07-28 Janssen Pharmaceutica Nv 3-aminopirazol triciclicos sustituidos en n como inhibidores receptores de pdfg.
RU2425677C2 (ru) 2005-01-21 2011-08-10 Астекс Терапьютикс Лимитед Соединения, предназначенные для использования в фармацевтике
CN101146532B (zh) 2005-01-21 2012-05-09 阿斯泰克斯治疗有限公司 药物化合物
JP2009513615A (ja) 2005-10-28 2009-04-02 アストラゼネカ アクチボラグ 癌の治療においてチロシンキナーゼ阻害剤として使用するための４−（３−アミノピラゾール）ピリミジン誘導体
JP2010505859A (ja) 2006-10-06 2010-02-25 アイアールエム・リミテッド・ライアビリティ・カンパニー タンパク質キナーゼ阻害剤およびそれを使用するための方法
KR101122481B1 (ko) 2007-05-04 2012-02-29 아이알엠 엘엘씨 Ｃ-ｋｉｔ 및 ｐｄｇｆｒ 키나제 억제제로서의 피리미딘 유도체 및 조성물
EA024729B1 (ru) * 2009-11-13 2016-10-31 Джиноско Киназные ингибиторы
GB201007286D0 (en) * 2010-04-30 2010-06-16 Astex Therapeutics Ltd New compounds
UA112425C2 (uk) 2010-12-13 2016-09-12 Еррей Біофарма Інк. ЗАМІЩЕНІ N-(1H-ІНДАЗОЛ-4-ІЛ)ІМІДАЗО[1,2-a]ПІРИДИН-3-КАРБОКСАМІДНІ СПОЛУКИ ЯК ІНГІБІТОРИ РЕЦЕПТОРНОЇ ТИРОЗИНКІНАЗИ ІІІ ТИПУ
US8877763B2 (en) * 2012-03-22 2014-11-04 Genosco Substituted pyridopyrimidine compounds and their use as FLT3 inhibitors
GB201205669D0 (en) 2012-03-30 2012-05-16 Agency Science Tech & Res Bicyclic heterocyclic derivatives as mnk2 and mnk2 modulators and uses thereof
MX2018006856A (es) 2015-12-07 2018-08-01 Plexxikon Inc Compuestos y metodos para modulacion de la quinasa, e indicaciones de los mismos.

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20130274255A1 (en) * 2012-04-12 2013-10-17 Development Center For Biotechnology Heterocyclic pyrazole compounds, method for preparing the same and use thereof

Also Published As

Publication number Publication date
JP2022545019A (ja) 2022-10-24
WO2021041276A1 (en) 2021-03-04
US12448394B2 (en) 2025-10-21
US20220289759A1 (en) 2022-09-15
CA3151821A1 (en) 2021-03-04
EP4017853A4 (en) 2023-08-30
BR112022003383A2 (pt) 2022-05-17
CN114502553B (zh) 2024-07-26
CN114502553A (zh) 2022-05-13
TW202115087A (zh) 2021-04-16
JP7651557B2 (ja) 2025-03-26
TWI759829B (zh) 2022-04-01
AU2020337883A1 (en) 2022-03-24
EP4017853A1 (en) 2022-06-29
KR20220051365A (ko) 2022-04-26
MX2022002062A (es) 2022-04-25

Similar Documents

Publication Publication Date Title
CN107922431B (zh) Hpk1抑制剂及其使用方法
JP5871896B2 (ja) Ｂ−ｒａｆキナーゼインヒビター
JP2025118762A (ja) ヘテロアリールアミノピリミジンアミドオートファジー阻害剤およびその使用方法
JP2024102236A (ja) Ｐｒｍｔ５阻害剤
JP5863058B2 (ja) １Ｈ−イミダゾ［４，５−ｃ］キノリン
CN117062818A (zh) 新型sos1抑制剂及其制备方法和应用
WO2018177403A1 (zh) 1H-咪唑[4,5-h]喹唑啉类化合物作为蛋白激酶抑制剂
TW202521536A (zh) Ｃｄｋ抑制劑
JP2021514373A (ja) Ｅｇｆｒ阻害剤としての新たなベンズイミダゾール化合物および誘導体
CN111072645B (zh) 作为TGF-βR1抑制剂的化合物及其应用
AU2017342928A1 (en) Quinoxaline compounds as type III receptor tyrosine kinase inhibitors
CA3078942A1 (en) Pyrrolotriazine compounds and methods of inhibiting tam kinases
EP4642767A1 (en) Pyrimidine carboxamide compounds
CA2946990A1 (en) Heterocyclic compounds and their use as dopamine d1 ligands
AU2020337883B2 (en) Heterocyclic pyrazole derivatives as type III receptor tyrosine kinase inhibitors
RU2833004C2 (ru) Производные гетероциклического пиразола как ингибиторы рецепторной тирозикиназы типа III
WO2024254490A1 (en) Pyrazolo-pyrimidinone compounds for use in methods of inhibiting wee1 a kinase
WO2025113625A1 (zh) 作为pkmyt1抑制剂的杂芳环和杂双环化合物及其应用
CA3211149A1 (en) Pharmaceutical compound
HK40057478A (en) Hpk1 inhibitors and methods of using same
HK40057478B (zh) Hpk1抑制剂及其使用方法
HK40043317A (en) COMPOUND AS TGF-β R1 INHIBITOR AND APPLICATION THEREOF

Legal Events

Date Code Title Description
FGA Letters patent sealed or granted (standard patent)